Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman
Replimune(US:REPL) Prnewswire·2025-09-19 04:40Accessibility StatementSkip Navigation REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline SAN FRANCISCO, Sept. 18, 2025 /PRNewswire/ -- On September 18, 2025, investors in Replimune Group, Inc. (NASDAQ: REPL) saw the price of their shares crater about 45% during intraday trading after the company announced that it completed a Type A meeting with the FDA on September 16 to discuss its Biologics License Application ("BLA") for lead drug candidate RP1 but "a path forward under ...